Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants

Stopped early · Phase 2 · Has a placebo group

Conditions studied: SARS-CoV-2

In brief

The study evaluated the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273.214 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in infants aged 12 weeks to \< 6 months.

Key facts

Study ID
NCT05584202
Run by
ModernaTX, Inc.
People needed
68
Starts
2022-09-30
Expected to finish
2024-11-15
Last updated by the study team
2025-11-26

Who can join

Age: 0 and older, up to 1. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.